Renal Denervation in Cardiovascular Diseases: Mechanisms, Evidence, and Expanding Applications
- 17 May 2026
- journal article
- review article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 108 (2) , 357-375
Abstract
Renal denervation (RDN) is a minimally invasive technique that disrupts renal sympathetic nerve activity, reducing sympathetic overdrive implicated in hypertension and other cardiovascular disorders. After early enthusiasm waned following SYMPLICITY HTN‐3, subsequent rigorously designed trials re‐established its efficacy. This review summarizes mechanistic insights, clinical evidence, and emerging applications of RDN. Data from randomized trials, meta‐analyses, registries, and translational studies were evaluated to assess their safety, efficacy, and broader therapeutic potential. Recent trials (SPYRAL HTN‐OFF MED, RADIANCE HTN‐TRIO, RADIANCE II) show consistent and durable systolic blood pressure reductions of approximately 5–10 mmHg with excellent safety. Beyond resistant hypertension, preliminary studies suggest benefits in heart failure (HFrEF and HFpEF), atrial fibrillation when combined with pulmonary vein isolation, chronic kidney disease, and metabolic syndrome. Mechanistic data reveal improved autonomic balance, regression of left ventricular hypertrophy, and possible renal protection. Limitations include procedural variability, incomplete nerve ablation, and the lack of large outcome‐based cardiovascular trials. Nevertheless, cost‐effectiveness analyses and recent ESC (2024) and AHA/ACC (2025) guidelines endorse RDN as a reasonable adjunct for resistant or uncontrolled hypertension. RDN offers sustained blood pressure control with a strong safety profile. Its expanding role across cardiovascular conditions positions it as a promising adjunctive therapy. Future outcome‐driven studies and standardized procedural approaches are needed to refine its place in clinical practice.Keywords
This publication has 68 references indexed in Scilit:
- Low-Dose Triple-Pill of Telmisartan, Amlodipine, and Indapamide for Initial Hypertension Treatment: A GRADE-Assessed Meta-analysis of Randomized TrialsHigh Blood Pressure & Cardiovascular Prevention, 2025
- The gut–heart axis in atrial fibrillation: Pathophysiology, evidence, and therapeutic potentialHeart Rhythm O2, 2025
- Geographic and demographic disparities in left–ventricular failure mortality, 1999–2020, with forecasts to 2040: A nationwide US analysisArchives of Cardiovascular Diseases, 2025
- The role of renal denervation for the treatment of hypertension in patients with chronic kidney disease: a position paper of the Italian Society of NephrologyJournal Of Nephrology, 2025
- Renal denervation in the setting of heart failureHeart Failure Reviews, 2025
- Ultra-long-term efficacy and safety of catheter-based renal denervation in resistant hypertension: 10-year follow-up outcomesClinical Research in Cardiology, 2024
- The role of renal denervation in cardiology and beyond: An updated comprehensive review and future directivesCurrent Problems in Cardiology, 2023
- Effects of catheter-based renal denervation on glycemic control and lipid levels: a systematic review and meta-analysisActa Diabetologica, 2021
- Effects of renal denervation on 24-h heart rate and heart rate variability in resistant hypertensionClinical Research in Cardiology, 2019
- Flow-mediated dilation, nitroglycerin-mediated dilation and their ratio predict successful renal denervation in mild resistant hypertensionClinical Research in Cardiology, 2018